AstraZeneca says FDA approves drug for rare kidney disease in adults

The FDA has granted accelerated approval to AstraZeneca's drug Ultomiris for treating adults with immunoglobulin A nephropathy, a rare kidney disease. The drug is the first and only approved C5 inhibitor targeting an immune pathway linked to kidney inflammation and could reduce the risk of kidney failure.

This Wire brief sits within Fusion42's coverage of Biotech.